Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
NCT ID: NCT06605599
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
161 participants
INTERVENTIONAL
2024-10-15
2025-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide.
Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
NCT07220460
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
NCT06024239
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
NCT06869187
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
NCT06696755
Antidepressant Therapy in Treating Bipolar Type II Major Depression
NCT00602537
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ABBV-932 Dose A
Participants will receive ABBV-932 Dose A.
ABBV-932
Oral Capsule
ABBV-932 Dose B
Participants will receive ABBV-932 Dose B.
ABBV-932
Oral Capsule
ABBV-932 Dose C
Participants will receive ABBV-932 Dose C.
ABBV-932
Oral Capsule
Placebo for ABBV-932
Participants will receive placebo.
Placebo for ABBV-932
Oral Capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABBV-932
Oral Capsule
Placebo for ABBV-932
Oral Capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a minimum score of 20 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
* Have a minimum score of 2 on Item 1 of the HAMD-17 at screening.
Exclusion Criteria
* Treated with any investigational drug within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug, is currently enrolled in another clinical study, or was previously enrolled in this study.
* Current use of any antipsychotic, antidepressant, anticonvulsant, mood stabilizer, herb, or over-the-counter medication with psychoactive potential within 1 week or 5 half-lives of the medication (whichever is longer).
* Prior exposure to ABBV-932 within 90 days prior to baseline.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Harmonex /ID# 267504
Dothan, Alabama, United States
Advanced Research Center /ID# 267716
Anaheim, California, United States
Axiom Research /ID# 267518
Colton, California, United States
Collaborative Neuroscience Research - Garden Grove /ID# 267654
Garden Grove, California, United States
Sun Valley Research Center /ID# 267708
Imperial, California, United States
Alliance for Research Alliance for Wellness /ID# 267492
Long Beach, California, United States
Excell Research /ID# 267541
Oceanside, California, United States
Viking Clinical Research Center - Temecula /ID# 267634
Temecula, California, United States
Accel Research Sites Network - St. Pete /ID# 267463
Largo, Florida, United States
GMI Florida - Central Miami Medical Institute /ID# 267566
Miami, Florida, United States
Allied Biomedical Res Inst Inc /ID# 267481
Miami, Florida, United States
K2 Medical Research - Orlando - South Orlando Avenue /ID# 267567
Orlando, Florida, United States
Segal Trials - West Broward Outpatient Research Site /ID# 267947
Tamarac, Florida, United States
Benchmark Research /ID# 267626
Shreveport, Louisiana, United States
CenExel /ID# 267675
Gaithersburg, Maryland, United States
Arch Clinical Trials /ID# 267507
St Louis, Missouri, United States
Duplicate_Oasis Clinical Research, LLC /ID# 267969
Las Vegas, Nevada, United States
Center For Emotional Fitness - Cherry Hill /ID# 267661
Cherry Hill, New Jersey, United States
Bio Behavioral Health /ID# 267493
Toms River, New Jersey, United States
Neurobehavioral Research /ID# 267564
Cedarhurst, New York, United States
New Hope Clinical Research - Inpatient unit /ID# 267465
Charlotte, North Carolina, United States
Quest Therapeutics of Avon Lake /ID# 267558
Avon Lake, Ohio, United States
OSU Psychiatry Department /ID# 267730
Columbus, Ohio, United States
Sooner Clinical Research /ID# 267639
Oklahoma City, Oklahoma, United States
Lehigh Center for Clinical Research /ID# 267451
Allentown, Pennsylvania, United States
Suburban Research Associates - Media /ID# 267621
Media, Pennsylvania, United States
Coastal Carolina Research Center, LLC /ID# 267550
Charleston, South Carolina, United States
FutureSearch Trials of Dallas /ID# 267715
Dallas, Texas, United States
Perceptive Pharma Research /ID# 267563
Richmond, Texas, United States
Grayline Research Center /ID# 267466
Wichita Falls, Texas, United States
Northwest Clinical Research Center /ID# 267505
Bellevue, Washington, United States
Core Clinical Research /ID# 268534
Everett, Washington, United States
Kokura Mental Clinic /ID# 268031
Kitakyushu, Fukuoka, Japan
Kawamura Mental Clinic /ID# 268325
Sapporo, Hokkaido, Japan
Yutaka Clinic /ID# 268026
Sagamihara, Kanagawa, Japan
Kaku Mental Clinic /ID# 268020
Fukuoka, , Japan
Kuramitsu Hospital /ID# 268751
Fukuoka, , Japan
INSPIRA Clinical Research /ID# 267041
San Juan, , Puerto Rico
Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065
San Juan, , Puerto Rico
BDH Research /ID# 267025
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M23-894
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.